Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Aaron Mansfield, MD
Mayo Clinic, Rochester, MN
Principal Investigator - Elizabeth Johnson, MD
Mayo Clinic
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Feb 2015
- Primary completion
- 28 Dec 2016
- Completion
- 28 Dec 2016
- Last update posted
- 11 May 2018
- Registered enrollment
- 19
- Registry id
- NCT02222363
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.